福元医药(601089) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was approximately ¥822.43 million, representing a 14.06% increase compared to ¥721.06 million in the same period last year[10]. - Net profit attributable to shareholders was approximately ¥125.02 million, a 28.02% increase from ¥97.62 million in the previous year[10]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥113.01 million, reflecting a 19.15% increase from ¥94.80 million year-on-year[10]. - Total operating revenue for the first three quarters of 2022 reached ¥2,365,674,217.96, an increase of 15.7% compared to ¥2,043,484,650.29 in the same period of 2021[34]. - Net profit for Q3 2022 was ¥333,009,164.40, representing a 27% increase from ¥262,492,112.90 in Q3 2021[37]. - Earnings per share for Q3 2022 was ¥0.83, compared to ¥0.72 in Q3 2021, reflecting a 15.3% increase[37]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥4.09 billion, an increase of 90.04% compared to the previous year's end[10]. - Shareholders' equity attributable to the parent company was approximately ¥3.07 billion, a significant increase of 153.33% from ¥1.21 billion year-on-year[10]. - Total current assets as of September 30, 2022, reached RMB 3,159,617,178.11, a significant increase from RMB 1,279,419,125.39 in the previous year[24]. - Total liabilities included accounts payable of RMB 114,057,259.70, down from RMB 129,768,747.00, indicating a decrease of about 12%[27]. - The total liabilities increased to ¥1,017,228,732.47, compared to ¥937,856,701.97 in the previous year, marking an 8.5% rise[34]. Cash Flow - The company reported a net cash flow from operating activities of approximately ¥413.60 million for the year-to-date period, up 5.04% from ¥393.76 million in the previous year[10]. - The net cash flow from operating activities for the first three quarters of 2022 was CNY 413,598,745.35, an increase from CNY 393,758,907.86 in the same period of 2021, representing a growth of approximately 3.4%[39]. - Total cash inflow from operating activities amounted to CNY 2,363,991,325.60, compared to CNY 2,078,714,633.90 in the previous year, indicating an increase of about 13.7%[39]. - Cash outflow from operating activities was CNY 1,950,392,580.25, up from CNY 1,684,955,726.04 in 2021, reflecting a rise of approximately 15.7%[39]. - The net cash flow from financing activities was CNY 1,510,419,345.07, contrasting with a negative flow of CNY -28,594,405.95 in the same period of 2021[40]. Shareholder Information - The company reported a total of 53,852 common shareholders at the end of the reporting period[20]. - The top ten shareholders collectively hold 99.99% of the company's shares, with the largest shareholder owning 36.73%[20]. Expenses and Investments - Research and development expenses rose to ¥171,277,340.73, up 42.3% from ¥120,389,823.11 in the previous year[34]. - The company received CNY 100,000,000.00 from other investment-related cash activities, down from CNY 415,000,000.00 in the previous year[39]. - The company paid CNY 407,896,428.45 to employees, which is an increase from CNY 353,444,711.06 in the previous year, reflecting a rise of about 15.4%[39].